How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Lanadelumab for preventing recurrent attacks of hereditary angioedema [ID1268]

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lanadelumab

Marketing authorisation indication

Lanadelumab (Takhzyro, Shire) is indicated for routine prevention of recurrent attacks of hereditary angioedema in patients aged 12 years and older.

Dosage in the marketing authorisation

The recommended starting dose is 300 mg lanadelumab every 2 weeks. In patients who are stably attack free on treatment, a dose reduction of 300 mg lanadelumab every 4 weeks may be considered, especially in patients with low weight. It is administered as a subcutaneous injection.

Price

The list price for lanadelumab is £12,420 per 300 mg vial.

The company has a commercial arrangement (simple discount patient access scheme), which would have applied if the technology had been recommended.